title: [Indigenous and imported low molecular weight heparin in the treatment of chronic hepatitis B and cirrhosis with hepatitis B virus: a prospective randomized controlled clinical study].
abstract: OBJECTIVE
  To evaluate the effect of indigenous and imported low molecular weight heparin (LMWH) in the treatment of chronic hepatitis and hepatic cirrhosis aiming at seeking a safe and effective anti-fibrosis therapy.
  
  
  METHODS
  A prospective randomized controlled clinical study of the treatment of patients with chronic hepatitis B using indigenous and imported LMWH was performed. Seventy-five patients were randomly divided into three groups: conventional treatment group (n=15), conventional treatment plus imported LMWH treatment group (n=30) and conventional treatment plus indigenous LMWH treatment group (n=30). The clinical parameters and treatment results in three groups were compared.
  
  
  RESULTS
  Three weeks after treatment, Child-Pugh scores in LMWH treatment groups were significantly lower than that in conventional treatment group (all P<0.05), hepatic function, serum PIII P and type IV collagen levels and portal vein blood flow velocity were much better (all P<0.05), levels of serum prealbumin were significantly elevated (all P<0.05). There were no significant differences between two groups with LMWH treatment. Subcutaneous hemorrhage, incidence of hematoma was lower (10.0% vs. 33.3%, P<0.05), area of ecchymosis was smaller [(0.004 2+/-0.012 7) cm(2) vs. (0.01 64+/-0.027 8) cm(2), P<0.05], and pain was released (8.3% vs. 81.0%, P<0.05) in conventional treatment plus indigenous LMWH treatment group than in conventional treatment plus imported LMWH treatment group.
  
  
  CONCLUSIONS
  LMWH in combination with conventional treatment for patients with cirrhosis of liver, significantly improves the outcome, indigenous LMWH calcium is a safe and effective anti-fibrosis drug as imported LMWH, also the price is lower and pain is less intense during injection than the latter.
authors.affiliation: Institute of Liver Disease, Hangzhou Sixth People's Hospital, Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310014, Zhejiang, China.
authors.forename: Jin-song
authors.initials: JS
authors.lastname: Huang
authors.forename: Xin
authors.initials: X
authors.lastname: Luo
authors.forename: Ji-xian
authors.initials: JX
authors.lastname: Yu
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Xiao-wei
authors.initials: XW
authors.lastname: Chen
authors.forename: Lei
authors.initials: L
authors.lastname: Xie
authors.forename: Xiong-ying
authors.initials: XY
authors.lastname: Zhu
authors.forename: Gong-ying
authors.initials: GY
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight